Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Glioblastoma × daratumumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 193 Recurrence 21 Neoplasms, Plasma Cell 14 Immunoglobulin Light-chain Amyloidosis 11 Neoplasms 10 Leukemia, Myeloid, Acute 8 Lymphoma, Non-Hodgkin 7 Smoldering Multiple Myeloma 5 Neoplasm, Residual 4 Hematologic Neoplasms 4 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Plasmacytoma 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Hodgkin Disease 3 Carcinoma, Non-Small-Cell Lung 3 Waldenstrom Macroglobulinemia 2 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Paraproteinemias 2 Myelodysplastic Syndromes 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Hematologic Diseases 2 Disease 2 Acute Kidney Injury 2 Urologic Neoplasms 1 Renal Insufficiency 1 Proteostasis Deficiencies 1 Primary Myelofibrosis 1

Interventions

Temozolomide 373 Radiotherapy 187 Bevacizumab 143 Radiation 73 Magnetic Resonance Spectroscopy 67 Lomustine 45 pembrolizumab 38 Surgical Procedures, Operative 37 Irinotecan 37 Carmustine 37 Nivolumab 27 Carboplatin 25 Specimen Handling 24 Radiosurgery 23 Erlotinib Hydrochloride 23 Radiotherapy, Intensity-Modulated 20 Chemotherapy, Adjuvant 20 Aminolevulinic Acid 19 Cyclophosphamide 18 Drug Therapy 17 sargramostim 16 O(6)-benzylguanine 14 Radiotherapy, Conformal 13 Granulocyte-Macrophage Colony-Stimulating Factor 13 Blood Specimen Collection 13 Everolimus 12 temsirolimus 11 Vorinostat 11 Sunitinib 11 Imatinib Mesylate 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04922723 2025-04-18

PRIDE

West Virginia University

Phase 1/2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡